Substance
GLUCAGON
Global reference: every product and company linked to this substance.
- cas: 16941-32-5
- ncit: C520
- pubchem_cid: 16132283
- rxnorm: 4832
- unii: 76LA80IG2G
BAQSIMI · GLUCAGEN · glucagon [INN] · GLUCAGON [JAN] · Glucagon [WHO-DD] · GVOKE HYPOPEN
Revenue by product (5)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK | GVOKE HYPOPEN | Q2 2026 | $22.5M |
| XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK | GVOKE KIT | Q2 2026 | $22.5M |
| XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK | GVOKE PFS | Q2 2026 | $22.5M |
| XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK | GVOKE VIALDX | Q2 2026 | $22.5M |
| AMPHASTAR PHARMACEUTICALS INC. COMMON STOCK | BAQSIMI | Q2 2026 | $0.1M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (6)
- BAQSIMI · AMPHASTAR PHARMACEUTICALS INC. COMMON STOCK
- GLUCAGON · ELI LILLY AND COMPANY COMMON STOCK
- GVOKE HYPOPEN · XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK
- GVOKE KIT · XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK
- GVOKE PFS · XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK
- GVOKE VIALDX · XERIS BIOPHARMA HOLDINGS INC. COMMON STOCK